Ultragenyx Pharmaceutical granted 48,561 restricted stock units to 17 non-executive officers to incentivize new hires.
Quiver AI Summary
Ultragenyx Pharmaceutical Inc. announced the grant of 48,561 restricted stock units to 17 newly hired non-executive officers as part of its Employment Inducement Plan, approved by the compensation committee on September 16, 2025. This initiative aligns with Nasdaq regulations and aims to incentivize new employees, with the units vesting over four years. Ultragenyx is dedicated to developing therapies for rare and ultra-rare diseases, focusing on unmet medical needs and effective drug development. The company's leadership has extensive experience in this field, emphasizing a commitment to delivering urgent and safe therapies. For more details, visit their website.
Potential Positives
- Ultragenyx Pharmaceutical Inc. has successfully attracted 17 new non-executive officers, enhancing its leadership and expertise in rare disease therapeutics.
- The grant of 48,561 restricted stock units aligns the interests of new employees with the long-term success of the company, potentially driving performance and innovation.
- The awards were approved by the compensation committee, demonstrating sound governance practices and a commitment to strategic hiring.
Potential Negatives
- The grant of a substantial number of restricted stock units to newly hired non-executive officers may raise concerns about excessive executive compensation during a time when significant transparency regarding company financial performance was not provided.
- There is a potential perception that the need to offer inducement stock grants suggests difficulty in attracting talent, which could indicate underlying issues with the company culture or competitive positioning in the industry.
- By not disclosing any specific financial metrics or performance indicators alongside the press release, it may lead to skepticism regarding the company's financial health and long-term sustainability.
FAQ
What is the recent stock grant by Ultragenyx Pharmaceutical?
Ultragenyx granted 48,561 restricted stock units to 17 newly hired non-executive officers as an employment inducement.
When were the restricted stock units granted?
The restricted stock units were granted on September 16, 2025.
How do the restricted stock units vest?
The stock units vest over four years, with 25% vesting each year on the anniversary of the grant date.
What is the purpose of the Ultragenyx Employment Inducement Plan?
The plan is designed to attract new employees by providing stock awards as part of their compensation package.
What is Ultragenyx's focus as a biopharmaceutical company?
Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases with high unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RARE Congressional Stock Trading
Members of Congress have traded $RARE stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RARE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 08/08, 07/15 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RARE Insider Trading Activity
$RARE insiders have traded $RARE stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $RARE stock by insiders over the last 6 months:
- CORAZON (CORSEE) D. SANDERS sold 2,405 shares for an estimated $89,922
- KARAH HERDMAN PARSCHAUER (EVP and Chief Legal Officer) sold 2,450 shares for an estimated $76,366
- ERIC CROMBEZ (EVP and Chief Medical Officer) has made 0 purchases and 2 sales selling 762 shares for an estimated $28,901.
- THEODORE ALAN HUIZENGA (SVP, Chief Accounting Officer) sold 84 shares for an estimated $2,636
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RARE Hedge Fund Activity
We have seen 165 institutional investors add shares of $RARE stock to their portfolio, and 181 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 2,951,397 shares (+953.7%) to their portfolio in Q2 2025, for an estimated $107,312,794
- FMR LLC added 2,223,166 shares (+582.9%) to their portfolio in Q2 2025, for an estimated $80,834,315
- BAKER BROS. ADVISORS LP added 1,196,578 shares (+75.9%) to their portfolio in Q2 2025, for an estimated $43,507,576
- ASSENAGON ASSET MANAGEMENT S.A. added 947,865 shares (+439.0%) to their portfolio in Q2 2025, for an estimated $34,464,371
- FARALLON CAPITAL MANAGEMENT LLC added 898,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $32,651,280
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 619,526 shares (-28.8%) from their portfolio in Q2 2025, for an estimated $22,525,965
- WELLINGTON MANAGEMENT GROUP LLP removed 577,678 shares (-23.6%) from their portfolio in Q2 2025, for an estimated $21,004,372
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RARE Analyst Ratings
Wall Street analysts have issued reports on $RARE in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/09/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/05/2025
- Canaccord Genuity issued a "Buy" rating on 08/08/2025
- Morgan Stanley issued a "Overweight" rating on 07/14/2025
- Guggenheim issued a "Buy" rating on 06/20/2025
- William Blair issued a "Outperform" rating on 05/28/2025
- JP Morgan issued a "Overweight" rating on 03/27/2025
To track analyst ratings and price targets for $RARE, check out Quiver Quantitative's $RARE forecast page.
$RARE Price Targets
Multiple analysts have issued price targets for $RARE recently. We have seen 9 analysts offer price targets for $RARE in the last 6 months, with a median target of $65.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $80.0 on 09/09/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $105.0 on 09/05/2025
- Whitney Ijem from Canaccord Genuity set a target price of $128.0 on 08/08/2025
- Jeffrey Hung from Morgan Stanley set a target price of $55.0 on 07/14/2025
- Laura Chico from Wedbush set a target price of $34.0 on 07/14/2025
- Tiago Fauth from Wells Fargo set a target price of $65.0 on 07/10/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $64.0 on 06/20/2025
Full Release
NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of the company’s common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
